Arginine methyltransferase inhibitor 1 exhibits antitumor effects against cervical cancer in vitro and in vivo

Pharmazie. 2018 May 1;73(5):269-273. doi: 10.1691/ph.2018.8365.

Abstract

Protein arginine methyltransferase 5 (PRMT5), a type II PRMT, is highly expressed in several types of tumors including cervical cancer. Arginine methyltransferase inhibitor 1 (AMI-1) inhibits solid tumors by targeting PRMT5. However, the effect of AMI-1 on cervical cancer is still unknown. In this study, we provided the first evidence that AMI-1 reduced cervical cancer cell proliferation, colony formation and promoted cell apoptosis in vitro. Suppression of tumorigenicity was also confirmed in vivo. Mechanistic studies revealed that AMI-1 significantly reduced PRMT5 level in cells and mice xenografts model of cervical cancer. These results suggest that AMI-1 inhibits cervical cancer by type II PRMT5.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Eukaryotic Initiation Factor-4E / metabolism
  • Female
  • HeLa Cells
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Naphthalenesulfonates / pharmacology*
  • Protein-Arginine N-Methyltransferases / antagonists & inhibitors*
  • Protein-Arginine N-Methyltransferases / metabolism
  • Urea / analogs & derivatives*
  • Urea / pharmacology
  • Uterine Cervical Neoplasms / drug therapy*
  • Uterine Cervical Neoplasms / enzymology
  • Uterine Cervical Neoplasms / pathology
  • Xenograft Model Antitumor Assays

Substances

  • 7,7'-carbonylbis(azanediyl) bis(4-hydroxynaphthalene-2-sulfonic acid
  • Antineoplastic Agents
  • Eukaryotic Initiation Factor-4E
  • Naphthalenesulfonates
  • Urea
  • PRMT5 protein, human
  • Protein-Arginine N-Methyltransferases